Introduction
The CNS is a complex organ, to say the least. Numerous cell types act in accord to maintain its integrity and its functions, separated into three main groups: neurons, the glia, and endothelial cells. Previously thought to be outnumbered 10:1, new data estimate that neurons are present in equal proportion to glial cells across the CNS, although this ratio is highly variable, depending on the region studied (Azevedo et al., 2009) . A clear count of the number of endothelial cells across the CNS has not been reported, although it was shown that endothelial cells and neurons are present in similar amounts in the amygdaloid complex (García-Amado and Prensa, 2012) . In any case, neurons, glial cells, and endothelial cells exist in close proximity of each other, forming the neurovascular unit (NVU), a coherent view of the CNS as a whole instead of a blend of compartmentalized cell types (Zlokovic, 2008) . When it comes to its defense, the CNS also has highly peculiar specificities. Devoid of a lymphatic system, its integrity is guarded exclusively through an innate immune system with an adaptive immunity only present in specific conditions (Rivest, 2009) . The term ''immune privilege'' has often been used to describe the defenses of the CNS. While it is true that specific responses are in place in this organ, the same can be said for every organ in the body. For instance, the lungs respond to a given insult in a specific way that might not be as efficient as in the spleen. In a way, every organ in the body is immune privileged. Such a term also suggests that immune processes are not as important in the CNS as in other organs. The innate immune system, however, is highly active in the CNS, organizing a complex response involving every cell type present.
Another concept regarding the integrity of the CNS that needs to be tackled is that, in normal physiology, the blood-brain barrier (BBB) is a hermetic wall shielding the CNS from any outside contacts. However, the BBB is actually a tightly controlled membrane through which active transport is organized and plays a central role in the control of innate immune responses. We will strive in this Review to highlight the importance and frequency of immune responses in the CNS and also to show the need of seeing such responses as a continuous crosstalk between numerous cell types in the CNS and the periphery, not as a linear event. The CNS is not an island separated from the rest of the body but rather an integral member of it, in constant link with its environment.
The Blood-Brain Barrier
In humans, one-fifth of the body's total energy consumption takes place in the CNS. It is therefore an excessively vascularized organ for the efficient intake of oxygen and nutrients. In constant and close contact with neurons, the BBB is one of the most important sites for the control of the CNS microenvironment and homeostasis. As such, the BBB fulfills two main functions: a physical barrier and a selective exchange barrier. While the BBB has long been seen as a staunch wall guarding the CNS, recent evidence demonstrates that this barrier is a lot more plastic and adaptive than was first assumed. The First Line of Defense The BBB mechanically separates the CNS from the circulation by the presence of specialized endothelial cells tightly attached to each other via tight junctions (TJs) and adherens junctions (AJs) (Hermann and Elali, 2012; Hawkins and Davis, 2005) . TJs are formed by transmembrane proteins such as occludin, claudins, and junctional adhesion molecules (JAMs). AJs, on the other hand, are constituted by the single-pass transmembrane glycoprotein cadherins such as cadherin-E, cadherin-P, and cadherin-N (Schulze and Firth, 1993; Takeichi, 1995) . The role for these junctions is to restrict and prevent blood-borne molecules and peripheral cells from entering the CNS (Wilson et al., 2010; Pardridge, 2003) . The presence of these TJs also gives to the BBB, a polarized structure comprising two functionally distinct sides: the luminal side facing the circulation and the abluminal side facing the CNS parenchyma ( Figure 1A ). While the cerebral endothelial cells of the luminal side interact intensively with bioactive molecules and immune cells in the circulation, the abluminal side interacts with the basal lamina: extracellular matrix proteins (EMPs), bioactive molecules (cytokines, growth factors, etc.), and cells of the parenchyma (Hermann and Elali, 2012) . The deregulation of TJs and AJs is central in innate immune responses of the CNS. They are highly sensitive to major cytokines produced during such a response such as Tumor Necrosis Factor a (TNF-a), , and IL-6 (Minagar and Alexander, 2003; Duchini et al., 1996) .
The BBB is also the interface between the CNS and the circulation, tasked with maintaining an adequate microenvironment for optimal neuronal function. Therefore, the permeability of the barrier is complemented by a number of sophisticated methods of transport that selectively control the exchange between CNS parenchyma and blood circulation. The BBB restricts the passage of toxic peptides into the CNS, among which is amyloid-b (Ab) (Mackic et al., 2002) . In parallel, it tightly controls the passage of other peptides required for neuronal function, via specialized peptide carriers expressed in the BBB (Deane et al., 2008; Zlokovi c et al., 1987) . These include ion channels, water channels, pumps, membrane receptors, carriers, and transporters. Ion channels such as Kir4.1 control the gradients of numerous crucial electrolytes for optimal neuronal functions (K + , Na + , Ca 2+ , etc.) (Butt and Kalsi, 2006) , while water channels, mainly Aquaporin 4, evacuate the water produced by glucose metabolism (Amiry-Moghaddam and Ottersen, 2003) . Although cerebral endothelial cells exhibit low endocytosis activity, selective and tightly controlled trans-cellular transport mechanisms The blood-brain barrier (BBB) maintains an adequate microenvironment for optimal neuronal function due to its physical and selective exchange characteristics. The presence of tight junctions (TJs) and adherens junctions (AJs) among brain endothelial cells is the main physical property of the BBB. (A) TJs are formed by transmembrane proteins, i.e., occludin, claudins, and junctional adherens molecules (JAMs), that interact with cytosolic adaptor proteins, i.e., guanylate kinase-like proteins (MAGUKs, i.e., zonula occludens [ZO]1, ZO2 and ZO3), cingulin, afadin (AF6), and 7H6, which act as scaffolds for the transmembrane proteins and connectors of TJs to the cytoskeleton. TJ formation induces polarization of brain endothelial cells and the formation of endothelial membranes with luminal (facing blood circulation) and abluminal (facing brain parenchyma) sides. AJs are formed by the transmembrane glycoprotein VEcadherin that interacts with cytosolic adaptor proteins, i.e., a-, b-, g-and p120 catenin, and the platelet endothelial cell adhesion molecule-1 (PECAM-1) homophilic interaction with adjacent proteins. The selective exchange characteristics are due to the presence of sophisticated active transport mechanisms, such as ABC transporters, i.e., ABCB1, ABCG2 (endothelial luminal side), and ABCC1 (endothelial abluminal side), water channels, i.e., AQP4 (astrocyte endfeet), and solute carriers, i.e., Glut-1 (both endothelial luminal and abluminal sides). (B) Although tight and highly selective, several molecules and cells can still cross the BBB under physiological and pathophysiological conditions by using several narrowly controlled routes, such as (1) receptor-mediated endocytosis route, i.e., transferrin receptor, insulin receptor, and LRP-1; (2) diffusion route for hydrophilic low molecular weight molecules that can be used by immune cells, bacteria, and viruses to infiltrate into the CNS; and (3) the nonspecific endocytosis route, i.e., fluid-phase and adsorptive endocytosis, which can be hijacked by immune cells, bacteria, and viruses to enter brain parenchyma. EC, endothelial cells; P, pericytes; A, astrocyte endfeet; M, microglia. exist, via either nonspecific endocytosis or receptor-mediated endocytosis. Nonspecific endocytosis includes fluid-phase endocytosis (the capture of soluble molecules by endothelial membrane vesicles) and adsorptive endocytosis (binding of molecules by endothelial membrane proteins) (Gloor et al., 2001) . Receptor-mediated endocytosis involves endothelial transmembrane receptors, such as the transferrin receptor (Zheng and Monnot, 2012) , the insulin receptor (Banks et al., 2012) , and the low-density lipoprotein (LDL) receptor-related proteins (LRPs), namely LRP-1 (Deane et al., 2008) . The family of ATP-binding cassette (ABC) transporters also plays a central role as efflux transporters for a wide range of lipophilic and amphipathic natural products, among which are bacterial, herbal, and fungal toxins. They act as a detoxification system by protecting neurons from toxic compounds present in their microenvironment (ElAli and Hermann, 2011) . The drug transporters ABCB1 and ABCG2 have been shown to be highly expressed at the luminal side of endothelial cells, acting as gatekeepers by impeding toxic compounds from CNS entry and accumulation ( Figure 1B ).
Entry of Immune Cells into the CNS
For decades, the immune privilege of the CNS was understood as an absence of an immune system inside the CNS, and the BBB was considered only as a barrier isolating the CNS from the peripheral immune system, preventing the entry of infectious agents and immune cells into the CNS (Pachter et al., 2003) . Extensive work in the last decade unravelled the presence of a specialized intrinsic innate immune system in the CNS (Rivest, 2009) , which was accompanied by several observations showing that the BBB is not a neutral and passive barrier, from an immunological point of view, but rather contributes actively to the immune response of the CNS (Muldoon et al., 2013) . More precisely, several data sets showed that the peripheral immune cells can still cross an intact BBB (Carson et al., 2006) , and the latter can modulate the function and control the fate of infiltrating cells (Ifergan et al., 2008) , outlining a more active role of the BBB in the CNS intrinsic innate immunity. While there is limited infiltration of peripheral immune cells into the CNS in physiological conditions, neutrophils, eosinophils, T lymphocytes, monocytes, and others can be found in the CNS parenchyma after injuries to the CNS, including infections and chronic diseases such as multiple sclerosis (MS) (Wilson et al., 2010) . However, the luminal side of the BBB is in constant contact with leukocytes patrolling the barrier. The advent of in vivo imaging techniques such as two-photon microscopy has allowed for the live imaging of cells constantly patrolling the brain vasculature (Coisne et al., 2013) and to better understand the importance of such a mechanism (Shechter and Schwartz, 2013) . Immune surveillance of the BBB is critical for the organism to respond to threats to the CNS. Leukocytes in the circulation bind endothelial cells of the BBB through adhesion molecules such as VCAM-1 and ICAM-1, sensing for distress signals from the CNS. Such a signal may be mediated via chemokines and cytokines released by microglia, astrocytes, and pericytes (Takeshita and Ransohoff, 2012) . The exact mechanisms of transmigration into the CNS are still unknown, although it is believed to occur by paracellular means, implying a loosening of the TJ between endothelial cells of the BBB (Sagar et al., 2012) . While detrimental in certain pathological cases such as multiple sclerosis, the recruitment of leukocytes into the CNS can play a beneficial role to help resident microglia in resolving certain insults (Simard et al., 2006) or even in gene therapy replacements (Cartier et al., 2009) .
The Point of Entry for Pathogens into the CNS The BBB, however, is not without fault. Under constant attack by pathogens, tightly regulated processes can become detrimental and actually contribute to the development of an infection. Pathogens enter into the CNS either by paracellular (between endothelial cells) or by trans-cellular (through them) mechanisms (Ley et al., 2007; Bencurova et al., 2011) . As a basic first line of defense, TJs are challenged by some infectious agents in order to weaken the physical properties of the BBB and infiltrate the CNS. The viral glycoprotein gp120 of HIV has been shown to breach the BBB by activating the chemokine receptors C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4) (Kanmogne et al., 2005; Andrá s et al., 2005) , resulting in TJ protein proteolytic degradation via proteasome (Nakamuta et al., 2008; Wang et al., 2011) . On the other hand, the meningococcal type IV pili bacteria have been reported to infiltrate into the CNS by recruiting the polarity complex Par3/ Par6/PKCzeta that governs TJ formation at the luminal side of the BBB. This results in the formation of ectopic intercellular junctional domains at the site of bacteria-cerebral endothelial cell interaction, depleting TJ proteins and consequently breaching the BBB (Coureuil et al., 2009) . Moreover, these bacteria can take advantage of the biased b2-adrenoceptor/b-arrestin signaling pathway in endothelial cells in order to tightly adhere to the luminal side of BBB and to delocalize TJ proteins, thus creating anatomical gaps through the BBB that bacteria can use to infiltrate into the CNS (Coureuil et al., 2010) . Transport mechanisms can also be used to trick cerebral endothelial cells into letting infectious agents cross the BBB. The adsorptive endocytosis takes place when glycoproteins in cerebral endothelial cell membrane bind other glycoprotein ligands in a lectin-like fashion. The internalized materials can be trafficked and transported either to lysosomes, to the Golgi complex/endoplasmic reticulum, or to the opposite cell membrane (Banks and Broadwell, 1994) . As cerebral endothelial cells do not express CD4 and galactosylceramide (Moses et al., 1993) , HIV-1 and HIV-infected immune cells use other routes to invade CNS parenchyma by using their own cell surface glycoproteins to engage the adsorptive endocytosis mechanism on cerebral endothelial cells in order to cross over the barrier formed by these cells, thus infiltrating and infecting the CNS (Banks et al., 1997) . Moreover, the poliovirus (PV) has been shown to cross the BBB via two mechanisms, either by exploiting the receptor-mediated endocytosis via the CD155 receptor (i.e., PV receptor, PVR) or by inducing caveolin-dependent endocytic mechanism at cerebral endothelial cells (Coyne et al., 2007) .
Moreover, it has been proposed that BBB breakdown could contribute to epilepsy pathogenesis. As such, BBB failure has been proposed to take place early in epilepsy pathogenesis, which causes the entry of blood-borne molecules into the brain, namely albumin (van Vliet et al., 2007) . Albumin extravasation triggers astrocytes' dysfunction by activating transforming growth factor b (TGFb)-receptor II (TGFb-RII), therefore exacerbating BBB dysfunction and initiating epileptic activity and seizures . This epileptic activity has been suggested to induce long-lasting innate immunity response and to promote infiltration of lymphocytes into the brain (Vezzani, 2005) .
Innate Immune Responses in the CNS
A complex immune reaction is engaged in the CNS in response to mechanical or ischemic traumas, viral or bacterial infections, or the accumulation toxic proteins. We discuss here the molecular bases of the innate immune response in the CNS. Pattern Recognition Receptors and the Control of the Innate Immune System In cases of infections, traumas, and pathological conditions, the CNS comes into contact with small protein patterns that regulate innate immunity, found in large numbers of microorganisms (Figure 2 ). Such patterns (coined PAMPs for pathogen-associated molecular patterns and DAMPS for danger-associated molecular patterns) include proteins from bacterial membranes such as peptidoglycans, intracellular proteins such as heatshock proteins, and nonprotein products such as ATP and urea and nucleic acid patterns such as nonmethylated CpGcontaining DNA, dsRNA, and ssRNA (Kumar et al., 2011) . These are recognized by pattern recognition receptors (PRRs), of which three major families exist: Toll-like receptors (TLRs), Nod-like receptors (NLRs), and RIG1-like receptors (RLRs). The role for these receptors in the CNS has been mostly studied in microglia, but astrocytes, oligodendrocytes, endothelial cells, and even neurons express functional levels of some of these receptors (Hanamsagar et al., 2012) . The engagement of such receptors results in the induction of specific pathways and the release of specific cytokines that play a role in resolving the injury. There are 11 TLR family members in humans and 13 in mice. A role for TLR1-9 has been described in the CNS and, while mostly active in microglia, TLRs are also found in neurons, astrocytes, and endothelial cells. TLRs can act alone or heterodimerize to create specific responses to a given stimuli. All TLRs except TLR3 signal through the adaptive protein Myd88, which leads to the induction of NF-kB and the release of cytokines, such as IL-1b, TNF-a, and IL-12. Conversely, TLR3 cannot activate Myd88 but signals through a TRIF-dependent pathway, leading Pattern recognition receptors (PRRs) recognize various parts of a pathogen to induce a number of signaling pathways centering mostly around adaptor proteins Myd88 and TRIF in order to stimulate transcription factors NF-kB or IRF3, respectively. These control the release of specific cytokines to attack the pathogen. Another level of control of the innate immune response is at the level of the inflammasome, a multiprotein complex centered around the activation of caspase 1, which produces active mature inflammatory cytokines IL-1b and IL-18 from their precursors. The pathway presented here is a simplified version of a much more complex pathway, a thorough discussion of which can be found in the literature (Kumar et al., 2011). to the induction of IRF3 and the production of other cytokines, such as IFNb. TLR4 can also signal through TRIF with the help of the adaptor protein TRAM. Both Myd88 and TRIF-dependent signaling pathways can also engage mitogen-associated protein kinase (MAPK) pathways, including ERK1/2, p38, and JNK, which lead to the stimulation of cell growth and the induction of inflammatory cytokine production (Brown et al., 2011) . For an in-depth review of TLR pathways, the reader can consult Hanke and Kielian (2011) and Rivest (2009) .
A function for NLRs in neuroinflammation is a rather recent discovery. Mostly known for their functions in the spleen and lymph nodes, there is much still to learn of their roles in the CNS. Among the 21 members of the NLR family, NLRP1-3, NLRP6, NLRP10, NOD1, and NOD2 show the highest level of expression in the CNS, mostly in microglia but also in astrocytes, oligodendrocytes, neurons, and endothelial cells for some subtypes (Rosenzweig et al., 2011) . Among these, NLRP3 and NOD2 have been the most studied so far because of their implication in autoinflammatory diseases of the CNS . NOD2 can respond to muramyl dipeptide (MDP, a PAMP from bacterial cell walls) and viral ssRNA (Ribes et al., 2012) . NOD2 activates NF-kB transcription through the adaptor protein RICK, which leads to the production of proinflammatory cytokines in response to MDP (Ribes et al., 2012) . In response to viral ssRNA, NOD2 activates the IRF3 transcription factor with the MAVS adaptor protein, leading to the release of type 1 interferons (Strober and Watanabe, 2011) . NLRP3 is normally in a repressed state, bound to specific chaperone proteins. The presence of an array of different signals can liberate and therefore activate NLRP3. Such signals include PAMPs, DAMPs, and intact pathogens (Zambetti et al., 2012) . Upon its release, NLRP3 activates the inflammasome, a complex of proteins that includes caspase-1, leading to the release of active IL-1b from a precursor (Zambetti et al., 2012) .
The final type of pattern recognition receptors, RIG-1-like receptors, is geared toward the recognition of viral nucleic acids in the cytoplasm (Creagh and O'Neill, 2006) . Three members of this family have been described so far: retinoic acid-induced gene 1 (RIG-1), melanoma differentiation-associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2). Acting similarly to some NLRs, RLRs recruit adaptor molecule MAVS and TRAF or the inflammasome to induce both IRF3 and NF-kB transcription, leading to the release of type 1 interferons and proinflammatory cytokines with antiviral properties, such as IL-1b and IL-18 (Yoneyama and Fujita, 2010) . All three members are expressed in the brain, with higher levels detected for LGP2 and RIG-1 by real-time PCR (Lech et al., 2010) . There is much still to learn regarding the role of RLRs in the brain, but both RIG-1 and MDA5 were shown to be implicated in the response to vesicular stomatitis virus (Furr et al., 2008) , the West Nile virus (Daffis et al., 2008) , and others. Both MDA5 and RIG-1 are expressed mostly by microglia and astrocytes (Chauhan et al., 2010) but also by neurons in which they contribute to the innate immune response to pathogens (Peltier et al., 2010) . Endpoint of the Innate Immune System: Cytokines and Phagocytosis The engagement of PRRs converges on NF-kB and/or IRF3 to induce the expression of cytokines (IL-1b, IL-6, TNFa, IL-18, IL-12, IFNb, TGFb, etc.), chemokines (MIP-1a, MCP-1, RANTES, etc.), reactive oxygen species (ROS), and free radicals. Describing the effects and roles of each cytokine is beyond the scope of this Review, as excellent Reviews on the subject can be found in the literature (Jaerve and Mü ller, 2012; Bellavance and Rivest, 2012; Akiyama et al., 2000) . For the purpose of this Review, we will discuss two major cytokines with radically different purposes: IL-1b and TGFb. IL-1b is a powerful proinflammatory cytokine produced in response to TLR activation in a Myd88-dependent manner, playing a key role in the early stages of innate immune reaction (Herx et al., 2000) . After TLR activation and NF-kB induction, IL-1b is produced at the NVU by microglia, cerebral endothelial cells, and astrocytes (Soulet and Rivest, 2008b) as an inactive protein that is proteolytically processed by the inflammasome to generate its active form (John et al., 2005) . IL-1b binds and activates its receptor complex formed by IL-1 receptor type I (IL-1RI) and IL-1RI accessory protein (IL-1RAP) (Steinman, 2013) , leading to NF-kB and activating protein-1 (AP-1) nuclear translocation and higher intracellular calcium concentration (Spö rri et al., 2001) . IL-1RI is present on the surface of cerebral endothelial cells, astrocytes, neurons, and microglia (Srinivasan et al., 2004; Van Dam et al., 1996) . Recently, an isoform of the IL-1RAP specific to the CNS was discovered, further defining the link between inflammation and neuronal survival . For decades, research on IL-1b has focused on its detrimental effects in neuroinflammation (Friedlander et al., 1997) . Recent studies reported new protective and regenerative functions of this cytokine in several CNS disease models, by mainly enhancing the production of insulinlike growth factor-1, ciliary neurotrophic factor, and NGF by astrocytes and microglia (Mason et al., 2001; Herx et al., 2000; DeKosky et al., 1996) . In parallel, IL-1b signaling seems to have a major role in BBB functions, as it has been shown to modulate BBB physical permeability and potentially enhanced immune cell infiltration into CNS (Argaw et al., 2006) .
TGFb is a multifunctional cytokine involved in immunosuppression and the control of cellular proliferation and extracellular matrix (ECM) production. Members of this family are produced as inactive precursors that are maturated in the trans-golgi into large latent complexes that are released to the ECM. After a conformational change (controlled by integrins, ROS, pH, and others), active TGFbs are exposed to their receptor binding sites. These signal largely through an Smad2/3-dependent mechanism leading to the recruitment of Smad4 and the induction of gene expression (Kaminska et al., 2013) . TGFb and TGFb receptor expression has been found in every cell type of the CNS. It has effects on neuronal survival, microglia migration, and phagocytosis and has angiogenic potential on cerebral endothelial cells (Beck and Schachtrup, 2012) . Its most documented effects, however, are carried out in astrocytes by promoting its migration, inhibiting its proliferation, and increasing the production of ECM components (Kaminska et al., 2013) . Microglia: Powerhouse of the Innate Immune System in the CNS Considered tissue-resident macrophages much like Kupffer cells for the liver or histiocytes in connective tissues, microglia are the only cells in the CNS that are of hematopoietic origin (Soulet and Rivest, 2008b) . Fate-mapping analysis has demonstrated that hematopoietic precursors from the yolk sac populate the CNS before the eighth embryonic day in mice (Ginhoux et al., 2010) . Once present, microglia are capable of self-renewal and do not require replenishment for circulating monocytic precursors (Ajami et al., 2007) . They are thus distinct from the monocyte lineage of cells and other tissue-specific macrophages such as Kuppfer cells in the liver, for which the maintenance is dependent upon the recruitment of bone marrow-derived cells (BMDCs) from the circulation (Klein et al., 2007) . In the CNS, initial reports suggested that the recruitment of BMDCs was an active event in normal physiology (Simard and Rivest, 2004) . After an intense debate on the subject (Soulet and Rivest, 2008a) , a consensus appears to have been reached following new experimental evidence that BMDC recruitment is a marginal effect in normal physiology (Lampron et al., 2012) but important in pathological conditions affecting the integrity of the CNS such as stroke (Schilling et al., 2009) , multiple sclerosis (Floris et al., 2004) , amyotrophic lateral sclerosis (Vaknin et al., 2011) , and others. This recruitment can be beneficial or harmful, depending on the condition studied (Shechter and Schwartz, 2013) .
In their native state, microglia are highly ramified cells with a small cellular body. Its extended processes allow microglia to rapidly sense the presence of tissue damages or signs of infections through PRRs. Microglia are highly plastic cells, they respond rapidly to the danger signals released by injured cells and secrete appropriate cytokines both to clear debris and to attract other microglial cells (Soulet and Rivest, 2008b) . They are specialized cells that respond to specific stimuli in a much more specific and ordered manner than was previously thought. To simplify the concept of microglial response, a dichotomy in the activation states of microglia was suggested. Based on the Th1/ Th2 and M1/M2 activation states of T cells and macrophages, respectively, two basic states were suggested for microglia, mostly dependent upon the nature of the stimulus. In the M1 activation state, also coined the classically activated or proinflammatory state and modeled in vitro by LPS stimulations, microglia show high levels of Ly6C expression and will secrete proinflammatory cytokines such as IL-1b and TNF-a and have a high phagocytosis and proteolysis potential (Martinez et al., 2008) . Through the release of iNOS and ROS, M1 monocytes are tuned for the clearance of bacterial infections. In the M2 state, also called the alternatively activated or tissue repair state and modeled in vitro by IL-4 or IL-10, microglia show lower levels of Ly6C expression and are geared toward tissue repair through the production of VEGF, chemokines, and extracellular matrix proteins (Boche et al., 2013) . However, in vitro experiments suggest that the polarization of microglia is a much more complex concept as each set of stimuli leads to the expression of specific proteins. For example, IL-4 and IL-10 both induce an M2 state but IL-4-stimulated microglia will be biased toward the killing and encapsulation of parasites, with high levels of arginase 1 expression, whereas IL-10-stimulated microglia show high potential of tissue remodeling with low levels of arginase 1 (Banchereau et al., 2012) . This led some investigators to further dissect the M2 state into three separate states (M2a, M2b, and M2c) (Martinez et al., 2008) . Most of the work on this polarization effect has been done in vitro, stimulating isolated microglia with a single stimulant such as LPS or IL-4. However, microglia are under the control of a complex network of PRRs leading to specific responses to a given stimulus both at the membrane by TLRs and in the cytoplasm by NLRs and RLRs (Figure 2 ). In the context of bacterial infection, for example, microglial cells are activated not only by proteoglycans from the cell walls but also by bacterial DNA, ATP, and other components of the bacteria. If we add to this the crosstalk between astrocytes, neurons, and microglia, each responding to the insult in their own way, we understand that limiting the activation state of microglia to only two basic steps might be a too simplistic view to reflect the complex response mounted in the CNS against a given insult. While the M1/M2 paradigm facilitates a discussion on a broad view of the role of microglia in a given situation, we suggest using more specific terms such as MS-polarized microglia in multiple sclerosis or AD-polarized microglia in Alzheimer's disease, for example.
The Neurovascular Unit: Cells of the Innate Immune System The tight coordination between neuronal and cerebrovascular functions is a prerequisite for a proper function of the CNS. Neuronal and BBB functions are tightly associated. Neurons, directly or indirectly via astrocyte processes, control BBB's functions based on their activity requirements (Koehler et al., 2009) . This coordination gives rise to an essential concept in understanding the physiology of the CNS: the NVU (Hermann and Elali, 2012) . The NVU represents cell-cell interactions, crosstalk, and signaling that are crucial and essential for proper functions of neurons. As such, it is conceivable that the NVU constitutes a dynamic interface contributing actively in CNS innate immunity. The importance of the NVU in the context of innate immunity relies on two main aspects: (1) the well-established roles of microglia, astrocytes, and the recently emerging roles of endothelial cells and pericytes in the innate immune responses and (2) the production of bioactive molecules upon the induction of innate immunity in the CNS by these cells, among which are several molecules that can potently modulate the functions of the BBB and consequently modulate immune responses of the CNS.
Endothelial Cells
Endothelial cells link peripheral immune responses to the CNS by acting as mediators and sensors of immune processes in the periphery. Due to their location at the luminal side of the BBB, endothelial cells are in continuous contact and crosstalk with blood circulation and are therefore under continuous challenges. Endothelial cells are considered the first line of defense, and recent data demonstrated an active role of these cells in innate immunity in the CNS (Danese et al., 2007) . Under physiological conditions, endothelial cells are immunologically quiescent, which is translated by downregulation of proinflammatory mediators and basal expression of adhesion molecules . TLRs' and NODs' expression and functionality are well documented in peripheral endothelial cells (Danese et al., 2007) . In cerebral endothelial cells, functional levels of TLR2/3/ 4/6 and TLR9 have been reported (Nagyoszi et al., 2010; Constantin et al., 2004 ). TLR2/6-specific stimulation in cerebral endothelial cells triggers ERK1/2 signaling pathway, inhibiting the expression of TJ proteins, thereby increasing endothelial paracellular permeability (Nagyoszi et al., 2010) . Interestingly, it has been reported that monocyte chemoattractant protein-1 (MCP-1, i.e., CCL2) and regulated and normal T cell expressed and secreted (RANTES, i.e., CCL5) can induce TLR2/6 activation during innate immune reactions upon immunization against respiratory syncytial virus (Murawski et al., 2010) . This observation would suggest that CCL2 and CCL5 can trigger TLR2/6 activation, which enhances cerebral endothelial cell paracellular permeability, delineating a possible coordination and crosstalk between monocytes and leukocytes with the BBB during neuroinflammatory process.
Tight and excessive adherence of immune cells to cerebral endothelium via adhesion molecules is mandatory for immune cells to successfully enter CNS parenchyma. Under normal conditions, cerebral endothelial cells exhibit basal expression of adhesion molecules. Once endothelial cells sense the presence of an immunological threat, they produce proinflammatory mediators, such as IL-1b (Creagh and O'Neill, 2006) , and surface-specific adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin-1 (ELAM-1) (Dinarello, 2009) . Immune cells use these adhesion molecules to migrate across cerebral endothelial cells mainly by loosening TJ contacts. For example, ICAM-1 crosslinks the lymphocyte function-associated antigen-1 (LFA-1) and induces downstream signaling pathway leading to cytoskeleton reorganization in cerebral endothelial cells and loosens TJs, thus facilitating leukocytes and B cell paracellular transmigration (Etienne-Manneville et al., 2000) . Moreover, the IL-1b-induced expression of ICAM-1 has been shown to enhance neutrophil infiltration into CNS across cerebral endothelial cells (Stanimirovic et al., 1997) . Furthermore, some transporters of the cerebral endothelium are targets of innate immune responses. ABC transporters play an important role in innate immunity, as it has been shown that inhibiting ABCB1 or ABCC1 on astrocytes reduced chemokine C-C motif ligand-2 (CCL2) release from these cells, resulting in decreased migration of monocytes across an in vitro model BBB (Kooij et al., 2011) . In parallel, several proinflammatory molecules are substrates of ABC transporters, implicating the latter directly in the immune response. For instance, ABCB1 has been shown to be involved in transporting the platelet-activating factor (PAF), steroids, and sphingosine-1-phosphate (S1P) (Honig et al., 2003; Rao et al., 1994; Raggers et al., 2001 ). In addition, systemic inflammation may affect the BBB function even before extravasation of immune cells. Such a response increases the production of proinflammatory cytokines in blood circulation, which can bind to their respective receptors on the surface of brain endothelial cells (Schiltz and Sawchenko, 2002) . This leads to the activation of enzymes (i.e., cyclooxygenase-2, nitric oxide synthase, etc.) and the production of bioactive molecules that have the ability to modulate BBB integrity (Laflamme et al., 1999; Schiltz and Sawchenko, 2002) , therefore facilitating the subsequent migration of immune cells into the brain parenchyma. Finally, the expression of several ABC transporters has been demonstrated to dramatically change once endothelial cells are exposed to the proinflammatory cytokine TNF and IL-1 (Figure 3) . Pericytes CNS pericytes belong to the lineage of vascular smooth muscle cells (vSMCs) and are physically the closest cells to CNS endothelial cells, forming peg-and-socket structures around them (Armulik et al., 2011) . Pericytes cover up to 30% of endothelial layer circumference and play an important role in regulating endothelial cell proliferation, survival, migration, and cerebrovascular branching (Hellströ m et al., 2001) . Pericytes are packed at the abluminal side of cerebral endothelial cells, controlling endothelial functions, and therefore play a central role in integrating luminal signals generated from cerebral endothelial cells to CNS parenchyma (Hermann and Elali, 2012) . Recent reports have shown that pericytes play an important role in CNS immunity at many levels. Being contractile cells, dysfunction of these cells reduces CNS microcirculation, deregulating regional cerebral blood flow (rCBF), which takes place before immune reaction (Ferná ndez- Klett et al., 2010; Bell et al., 2010) . Nitrosative stress induced by initiation of the innate immune response has a deep impact on pericyte functions by inducing continuous contraction, which results in blood entrapment in CNS capillary beds (Yemisci et al., 2009) , exacerbating the local immune responses. Moreover, numerous studies have outlined a possible function of pericytes as macrophages in the CNS based on the presence of a high number of lysosomes within their cytoplasm (Xiong et al., 2009) , their efficient capacity of internalizing tracers injected in blood circulation, and cerebrospinal fluid (CSF) (Rucker et al., 2000) , along with a potential for phagocytosis (Balabanov et al., 1996) and antigen presentation capacities (Hickey and Kimura, 1988) . Pericytes isolated from lung and CNS vasculature express functional TLR4, the activation of which regulated endothelial function and affected vascular permeability (Edelman et al., 2007; Balabanov et al., 1996) . Moreover, some studies showed that, while quiescent under physiological conditions, pericytes are capable of inducing their macrophage-like activity after TLR4 signaling induction (Graeber The communication between the CNS and the environment is a critical part of an innate immune response. This communication is effective in both directions, i.e., from the CNS into the circulation (A, inside-out) and from the circulation into the CNS (B, outside-in).
(A) The inside-out model. The stimulation of PRRs by pathogens or by toxic molecules in the CNS induces the production of a wide range of cytokines, chemokines, and growth factors. Among them, TNFa and IL-1b activate cytokine receptors expressed at the abluminal side of brain endothelial cells, leading to TJ loosening, the upregulation of adhesion molecule, such as ICAM-1, E-selectin, and P-selectin, and BBB opening. Moreover, TNFa and IL-1b activate cytokine receptors expressed on the surface of astrocytes and pericytes, inducing further production of CCL2 by the former and enhanced phagocytosis activity by the latter. CCL2 can be transported to the luminal side of the BBB by ABCB1 expressed on endothelial cells exacerbating infiltration of leukocytes and monocytes. (B) The outside-in model. The binding of pathogen molecules and proinflammatory cytokines to their receptors expressed on brain endothelial cells causes TJ deregulation and the upregulation of adhesion molecules, such as ICAM-1, E-selectin, and P-selectin. The enhanced and prolonged expression of these adhesion molecules increases adhesion of leukocytes to the luminal side of the BBB. The crosslink between LFA1 and ICAM-1 induces endothelial cell cytoskeleton reorganization and TJ loosening, creating a gap between endothelial cells, through which leukocytes and pathogens present in blood circulation can cross the BBB. Infiltrating leukocytes and pathogens trigger the activation of other PRRs expressed on microglia, astrocytes, and pericytes, leading to the production of several cytokines, chemokines, and growth factors, such as TNFa, IL-1b, CCL2, and GM-CSF. Balabanov et al., 1996) . Under such conditions, pericytes produce immune-active molecules, such as nitric oxide (NO), and a wide range of cytokines and chemokines, namely granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), CCL3, and CCL4 (Kovac et al., 2011) (Figure 3) .
Recently, pericytes have been given special attention for their roles in neurodegenerative diseases, namely AD. Pericytes induce BBB formation, mainly by downregulating genes associated with vascular permeability (Daneman et al., 2010) and inducing the activity of ABCB1 in brain endothelial cells (Al Ahmad et al., 2011) . Loss of pericytes has been proposed to initiate the pathogenesis of neurodegenerative diseases by causing a primary cerebral vascular injury (Winkler et al., 2011) . Consequently, the primary vascular injury leads to the extravasation of blood-borne molecules into brain parenchyma, leading to neuronal death (Winkler et al., 2011) . Perivascular Space Both pericytes and endothelial cells are ensheathed by the basal lamina, which is composed mainly of ECM proteins, such as collagen type IV, heparin sulfate proteoglycans, laminin, and fibronectin (Farkas and Luiten, 2001) , that constitutes the perivascular space and provides a physical support for endothelial cells and pericytes. Besides providing physical support, the perivascular space acts as a backup immune surveillance and scavenging center by constituting a niche for several immune cells that patrol CNS vasculature, namely perivascular microglia (Bechmann et al., 2001 ). The origin of perivascular microglia is not fully elucidated, but it is widely accepted now that they originate from the monocyte/macrophage lineage and are continuously and rapidly replaced by blood circulating bone marrow-derived cells (Gehrmann et al., 1995; Bechmann et al., 2001) . Although perivascular microglia perform normal microglial functions, they are different due to their interaction and crosstalk with cerebral endothelial cells. For instance, they have been shown to play a major role in supporting vascular integrity and repair (Ritter et al., 2006) . Perivascular space creates a special milieu that controls the behavior and fate of infiltrated immune cells. This has been unraveled by the presence of newly differentiated dendritic cells from a subset of CD14+ infiltrated monocytes when exposed to high concentrations of TGFb and GM-CSF (Ifergan et al., 2008) . Moreover, fibrinogen leakage and accumulation in the perivascular space have been shown to induce early perivascular microglial clustering toward CNS vasculature (Davalos et al., 2012) . Astrocytes Astrocyte endfeet ensheathe more than 90% of brain capillaries, and this interaction is crucial and essential in the function of the BBB. Astrocytes also act as scaffold cells by guiding neurons during development (Jacobs and Doering, 2010) and by orienting newly formed brain capillaries (Bozoyan et al., 2012) . Under physiological conditions, astrocytes communicate physically with the endothelium through ECM proteins that act as ligands for adhesion receptors, namely the integrin and dystroglycan that bridge astrocyte endfeet to endothelial cells (del Zoppo and Milner, 2006) . They are characterized by their capacity to produce and secrete a wide range of bioactive molecules that control endothelial function, such as VEGF, TGFb, bFGF, TNFa, IL-1b, IL-3, IL-6, Ang-1, B cell-activating factor (BAFF), and glial-derived neurotrophic factor (GDNF) (Igarashi et al., 1999; Chung and Benveniste, 1990; Farina et al., 2007; Abbott et al., 2006) . These play a crucial role in innate immune responses. Astrocytes have been shown to express TLR2/3/4/5/9 and NOD1/2 and can produce TNFa when stimulated with LPS (Chung and Benveniste, 1990) . Astrocytes act like an assistance and maintenance agent of innate immunity by supporting and orienting the beneficial effects of innate immune responses. This role of astrocytes was highlighted by using a mouse model of nonfunctional astrocytes, in which they have been shown to play a crucial role in controlling the immune responses, mediating BBB maintenance, and supporting neuronal survival and functions (Bush et al., 1999) .
Innate Immunity in Diseases of the CNS
Innate immunity reacts to all kinds of attacks on CNS integrity. These can be divided into four main groups: acute injuries (mechanical traumas, ischemic stroke, etc.), neurodegenerative chronic diseases (Alzheimer's disease, multiple sclerosis, etc.), brain tumors (glioblastomas), and infections (HIV, E. coli, etc.) . While there is a lot to discuss regarding the role of innate immunity in infection, stroke, and brain tumors, we will focus this part of the discussion on the implication of the innate immune system in two chronic diseases: Alzheimer's disease and multiple sclerosis. We will use these complex pathological states to highlight the integration of all cell types of the NVU and how they can be used efficiently to develop new comprehensive ways of targeting such diseases. Alzheimer's Disease Alzheimer's disease is caused mainly by the deposition of Ab into plaques in the CNS. The innate immune system plays a role in the development of the pathology as chronic exposure of microglia to Ab leads to uncontrolled inflammation, the release of toxic free radicals, and reactive oxygen species, as originally described in postmortem studies (Uchihara et al., 1997; Cagnin et al., 2001) . Furthermore, large scale genome-wide association studies (GWAS) of thousands of AD subjects have shown that among the ten genetic polymorphisms most tightly linked to the development of late onset AD, nine play a dominant role in immunological processes (Moraes et al., 2012) . In the serum, cerebrospinal fluid, and the cortex of affected patients, higher levels of IL-1b, IL-6, TNFa, IL-8, and TGFb have all been reported (for in-depth Reviews, see Rubio-Perez and MorillasRuiz, 2012 and Akiyama et al., 2000) . Similarly, both TLR2 and TLR4 are overexpressed in peripheral blood mononuclear cells from patients with AD . It also appears that the main monocytic chemoattractant CCR2 and its ligand CCL2 are involved in the progression of AD (Naert and Rivest, 2011; Conductier et al., 2010; Westin et al., 2012) . Furthermore, while no genetic association at the TLR4 locus was found in GWAS for AD (Moraes et al., 2012) , polymorphisms in the TLR4 gene were shown to increase the incidence of late-onset AD in populations from Italy (Balistreri et al., 2008; Minoretti et al., 2006) and China Yu et al., 2012; Chen et al., 2012) . The reported data on humans state that, in essence, AD is first and foremost an immunological disease.
The main genetic risk factor identified in GWAS for late-onset AD is ApoE4 (Bettens et al., 2013) . The family of Apolipoprotein E (ApoE) plays a major role in the transport of cholesterol and other lipids, mainly by the binding of LDLRs and LRPs (Mahley, 1988; Holtzman et al., 2012) . Humans have three common alleles of apoE gene, apoEε2, apoEε3, and apoEε4, which give rise to three protein isoforms, ApoE2, ApoE3, and ApoE4 . Biochemical studies have shown that ApoE4 has very weak affinity to its receptors and does not induce any signaling activity, whereas ApoE3 has very high affinity to its receptors and induces the activation of several signaling pathways downstream to its receptors (ElAli and Hermann, 2010) . ApoE has high expression levels in the brain, is produced mainly by astrocytes, and has been shown to have protective roles at the CNS Mahley, 1988) . It is a prime example of the importance of the NVU concept, integrating most cells present in the CNS. In addition to its role in cholesterol and lipid transport, ApoE has many other physiological and pathophysiological functions within the CNS . ApoE signaling pathway within the NVU constitutes the mediator that integrates the functions of different cells forming the NVU, therefore playing key roles in modulating BBB functions ElAli and Hermann, 2010) . More precisely, ApoE4 can alter the BBB by the formation of the cyclophilin A (CypA)/NF-kB complex in pericytes and matrix metalloproteinase-9 (MMP-9) production in the perivascular space, which may lead to ECM degradation. Interestingly, ApoE3 was able to reverse these detrimental effects of APoE4 . Moreover, ApoE is able to bind ApoE receptor 2 (LRP-8) on the surface of cerebral endothelial cells, which abolishes c-Jun phosphorylation and increases the expression of ABCB1 in the luminal side of the BBB (ElAli and Hermann, 2010) . ApoE may also act as endogenous immunomodulatory molecules for both innate and adaptive immunities in the CNS (Terkeltaub et al., 1991; Pepe and Curtiss, 1986) .
Whether the activation of the innate immune system is a cause or a consequence of the development of AD is still highly debated. In vitro studies showed that fibrillar Ab acts directly on microglia, activating TLR4 and TLR2 and the release of TNFa that leads to neuronal death, as demonstrated in microglial cell lines and microglia neuron coculture (Reed-Geaghan et al., 2009; Udan et al., 2008; Stewart et al., 2010) . On the other hand, in vivo studies in mouse models depict another picture. Knockouts or genetic inactivation of TLR4 (Tahara et al., 2006; Song et al., 2011) , TLR2 (Richard et al., 2008) , Myd88 (Michaud et al., 2011) , or TNFa receptors (Montgomery et al., 2011) in mouse models of AD have all aggravated the symptoms of the disease, including cognitive functions and amyloid deposition. These differences have led to a better understanding of inflammatory processes in AD. For multiple reasons (genetic predisposition, ineffective clearance, previous injuries, etc.), Ab starts to accumulate in the CNS into toxic oligomers and plaques. These are detected by microglia as DAMPs, activating a TLR2/4 response. Although microglia can be effective to clear Ab in vitro (Reed-Geaghan et al., 2009) , they alone cannot resolve the injury in vivo, as Ab production surpasses microglia's capacity for its clearance. Microglial cells then enter a nonresolving chronic inflammatory circle of continuous inefficient activation, thus contributing to disease progression, a process we like to call ''frustrated inflammation'' (Figure 4) .
The innate immune system, however, does possess a capacity for the clearance of Ab and can play a beneficial role in AD. This would explain the detrimental effects of knocking out completely the innate immune response, while beneficial effects of inhibiting selective parts of it can prove to be an efficient therapeutic strategy. This was highlighted by the failure of nonsteroidogenic antiinflammatory drugs (NSAIDs) to treat AD in large-scale clinical trials (Imbimbo, 2009) . Initial reports have shown that subjects on recurring treatments of NSAIDs had lower incidence of AD (McGeer et al., 1996) . The reason for the clinical failure was that it had been forgotten why the subjects on NSAIDs needed to receive these drugs in the first place: they have an overly active innate immune system that was helping prevent the development of AD. As such, a tightly regulated stimulation of While the pathological hallmark of AD remains Ab plaques and deposits, impaired microglial functions and a defect in monocytic cells seem to play a major role in the progression of the disease. They contribute to the increased Ab levels inside the CNS through inefficient clearance of circulating Ab and through ill-controlled inflammatory mechanisms leading to inefficient clearance of cerebral Ab deposits. These act in synergy to skew the sink effect in the wrong direction, leading to important Ab deposition, neurodegeneration, and ultimately cognitive decline. M-CSF has shown great promises as a therapeutic strategy for AD in animal models and clinical data in humans suggest that this molecule could prove efficient in the prevention of Ab deposits. Such a treatment regulates the count and function of circulating monocytes but also restores microglial function for an efficient clearance of Ab. If successful, these effects restore a positive sink effect of Ab outside of the CNS and would lead to cognitive improvement. innate immune processes, rather than its complete inhibition, is another way of designing new treatment options for AD. This can be achieved with the use of novel TLR ligands that can stimulate the clearance of Ab without inducing overt inflammatory processes. We have recently demonstrated the beneficial effects of monophosphoryl lipid A (MPL) in mouse models of AD (Michaud et al., 2013) . MPL, a detoxified TLR4 ligand, induced a high phagocytic potential in microglia, as much as LPS, while showing almost undetectable production of inflammatory cytokines or ROS. In AD mouse models, a chronic treatment with MPL reduced Ab production by up to 80% in some cases and normalized their cognitive behavior. This paves the way for the development of safe immunomodulatory therapies in AD as a monotherapy but also as complements to other Ab-lowering strategies such as vaccination.
Although most of the work in AD has focused on neurodegeneration and inflammatory processes, accumulating evidence shows that a dysregulation of the vasculature is just as important in the development of AD (Zlokovic, 2011) . Most of the work on the implication of innate immunity in AD has focused on the role of microglia. However, novel exciting research shows that the rest of the NVU is a prime candidate for the creation of new therapeutic strategies for AD. Pioneer work from the team of Zlokovic has shown that LRP-1, a specific transporter at the BBB, is critical in the clearance of Ab from the CNS into the circulation (Deane et al., 2004) . In further studies, the authors found that LRP-1 was upregulated upon LPS stimulation, therefore presumably enhancing pericytes and endothelial cells' capacity to internalize the toxic peptide Aß given the major role of LRP-1 in Aß processing (Deane et al., 2008) . Moreover, ABCB1 and ABCG2 have been shown to be involved in the elimination of Ab from the CNS (Xiong et al., 2009; Cirrito et al., 2005; van Assema et al., 2012) . In the other direction, the receptor for advanced glycation endproducts (RAGE) controls the transfer of Ab from the circulation into the CNS, either directly (Deane et al., 2003) or by facilitating the entry of Ab-laden monocytes into the CNS, thereby contributing to the development of the disease and another suitable target for treatment . We understand now that the levels of Ab in the brain are an equilibrium between its production and its clearance, reflected at the BBB as a balance between its entry and its exit from the CNS through the LRP-1/RAGE tandem. These results have helped develop the hypothesis that clearing Aß in the circulation could create a vacuum that pulls the Aß from the CNS into the circulation through these transporters. This so-called ''sink hypothesis'' warrants the targeting of the periphery to have positive effects in the CNS. One such compound is the macrophage-colony stimulating factor (M-CSF), the main growth factor for cells of the monocytic lineage (Hume and MacDonald, 2012) (Figure 4) . Injecting M-CSF to transgenic mice that spontaneously develop AD on a weekly basis prior to the appearance of learning and memory deficits prevented cognitive loss. The treatment also restored the population of M1 monocytes in the circulation and greatly decreased Ab levels. In addition, M-CSF treatment resulted in the stabilization of the cognitive decline state in transgenic mice that already had Ab pathology . In vitro, exposure of mouse microglia to M-CSF enables the acidification of their lysosomes and, subsequently, the degradation of internalized Ab (Majumdar et al., 2007) . In this regard, low levels of M-CSF were recently measured in patients with presymptomatic AD or mild cognitive impairment, which together with low levels of other hematopoietic cytokines predicted the rapid evolution of the disease toward a dementia diagnosis 2 to 6 years later (Ray et al., 2007) . This is one of the ways the hematopoietic system can be used to treat AD (Lampron et al., 2011) .
Multiple Sclerosis
Multiple sclerosis is a chronic neuroinflammatory CNS disorder with a widespread degradation of the myelin sheaths of axons. It is characterized by focal lymphocyte infiltration into CNS parenchyma, which is associated with BBB dysfunction and microglia activation (Cristante et al., 2013; Compston and Coles, 2008) . During the early stages of MS pathogenesis, the insults triggered by infiltrated lymphocytes are transient and both demyelination and neurological dysfunction are reversible. This is the relapsing-remitting phase of the disease. With time, the pathogenesis evolves to reach exacerbated inflammation, irreversible demyelination, and permanent neurological dysfunctions, leading to the formation of demyelinated plaques in the CNS, the progressive stage of the disease (Compston and Coles, 2008) . The early factors involved in MS pathogenesis are still largely unknown. However, lymphocyte infiltration, and its interaction with antigen-presenting cells of the CNS (mostly microglia), is seen as the crucial step in the early stages of MS pathogenesis (Minagar and Alexander, 2003) . Although myelinreactive T cells have been shown to be the most important infiltrates, recent data demonstrated an important role for B cells in the pathogenesis of MS, characterized by their specific proinflammatory polarization (von Bü dingen et al., 2012) . As such, the mechanisms by which T and B cells migrate through endothelial cells are key steps in the pathogenesis of MS and a prime target for novel therapeutic strategies.
At the molecular level, the local production of proinflammatory molecules such as TNF-a and IL-1b leads to elevated expression of adhesion molecules ICAM-1 and VCAM-1 (Dore-Duffy et al., 1993; Maimone et al., 1991) and chemokines such as CCL2, CCL5, and CCL3 (Prat et al., 2002) . These effects contribute to the recruitment and the attachment of circulating lymphocytes to the BBB. Lymphocytes migrate using two main routes. A paracellular route involves LFA-1/ICAM signaling that results in cytoskeleton reorganization and TJ opening leading to cellular infiltration. A transendothelial route involves the interaction between ICAM-1 and caveolae on inflamed endothelial cells inducing the formation of vesiculo-vacuolar organelles that create an intracellular duct through which leukocytes can migrate (Ley et al., 2007) . The contribution of the immune responses at the NVU was further highlighted by showing the capacity of astrocytes to produce and secrete CCL2, which enhanced both monocyte and leukocyte migration through the BBB (Weiss et al., 1998) . In humans, MRI techniques have revealed a positive correlation between MS active lesions, BBB permeability, perivascular cuffs (cerebral capillaries surrounded by plaques), and massive infiltration of monocytes (Minagar and Alexander, 2003) . BBB dysfunction is also a factor in experimental autoimmune encephalomyelitis (EAE), a widely used animal model of MS (Floris et al., 2004) . We have mentioned that inflamed cells of the BBB express and produce numerous cytokines and adhesion molecules, thereby augmenting the recruitment and infiltration of T cells. In addition, the presence of an inflammatory microenvironment at the NVU has been shown to play a crucial role in deciding the fate of infiltrated monocytes across the BBB by mediating the differentiation of infiltrated monocytes into dendritic cells that have been reported to be abundant in the perivascular space of MS lesions (Ifergan et al., 2008) . Numerous studies have also shown that microglial TLRs are upregulated in MS and EAE (Olson and Miller, 2004) . The contribution of the innate immune response was further outlined by the resistance of TLR4/9-and Myd88-deficient mice to EAE induction (Marta et al., 2009) . The exact role of astrocytes in MS is still debated. A recent study has shown that inducing an MS-like pathology in mice whose astrocyte population had been depleted does not prevent damages to the myelin sheaths. However, the clearance of damaged myelin by microglia was impaired, as astrocytes were not able to recruit phagocytic microglia to the damaged myelin, impeding oligodendrocytes to remyelinate the axons (Skripuletz et al., 2013) . This study illustrates the point that while inflammatory innate immune processes are clearly detrimental in the pathophysiology of MS, astrocytes and microglia also have crucial functions limiting the progression of the disease.
Within the NVU, MMPs play an important role in immunomodulation. Indeed, MMP-9 levels and activity have been shown to increase in MS lesions, CSF, and the plasma of MS patients (Fernandes et al., 2012; Leppert et al., 1998; Lindberg et al., 2001) . MMP-9 contributes in the pathogenesis of MS/EAE by acting as a mediator of leukocyte infiltration into the CNS, especially the proinflammatory T helper 1 (Th1) CD4+ lymphocytes (Abraham et al., 2005) . MMP-9 specifically induces the degradation of EMPs, creating ducts within the perivascular space, which are utilized by lymphocytes in order to invade the CNS (Agrawal et al., 2006) . In addition, MMPs induce the production of several chemokines and cytokines within the NVU structure, which deeply affect the migration and infiltration of immune cells into the CNS (Larochelle et al., 2011) . In MS and EAE, MMPs are mainly produced by activated lymphocytes and macrophages by specifically inducing the extracellular MMP inducer (EMMPRIN) factor . Interestingly, targeting EMMPRIN with a neutralizing antibody specifically decreased MMP-9 activity within lesion sites and consequently decreased leukocyte infiltration, which attenuated in EAE severity .
After three decades of advancement in the field, numerous therapeutic options have been developed for MS, including immunomodulators such as interferon-b, glatiramar acetate, and mitoxantrone. While these are effective in reducing the frequency of relapses, none of them can reverse the progression of the disease (Polman and Uitdehaag, 2003; Wiendl and Hohlfeld, 2009) , highlighting the need for the development of new therapeutic approaches for MS. Although the contribution of microglial cells in MS and EAE pathogenesis has been outlined as being detrimental, new emerging reports shed the light on a protective role for these cells in the context of MS and EAE, mainly by producing anti-inflammatory cytokines, such as IL-10 and TGF-b, and by acting as scavengers to eliminate toxic debris present in lesion sites, responses that seem to be dependent on the local inflammatory microenvironment (Napoli and Neumann, 2010) . Moreover, it was reported that Heat-shock protein 70 (Hsp70), an endogenous ligand of TLR2/4 present on microglia, is overexpressed in MS and EAE, which was suggested as a possible neuroprotective process triggered by neurons to rescue the system due to Hsp70's cytoprotective characteristics. Pharmacological approaches using molecules that induce and/or stabilize Hsp70 expression have been shown to ameliorate EAE outcome (Dello Russo et al., 2006) . Therefore, enhancing innate immune responses by Hsp70 induction and the subsequent activation of TLR2/4 could have beneficial effects on MS and EAE diseases and advocate for the positive role of the innate immunity in this context. High-mobility group box-1 (HMGB-1) is another endogenous TLR2/4 ligand (Maroso et al., 2010) , which seems to play an important role in amplifying the immune response in EAE and MS (Andersson et al., 2008) .
Autologous hematopoietic stem cell transplantation, a radical approach to target the immune system, has shown great benefits in humans (Burt et al., 2009) . The beneficial effects of such a strategy depend on the formation of a novel tolerant immune system and/or the long-lasting depletion of immunoreactive T cells (Figure 5 ).
Conclusion and Future Directions
The role played by the innate immune system in brain homeostasis and diseases is becoming one of the most studied subjects in neuroscience. We and many other groups have unraveled important mechanistic insights, although much remains to be done to understand how it can be modulated to fight against chronic diseases and help the recovery after injuries. Circulating monocytes are now considered a very important target since they act on the surface of the NVU to clear toxic proteins, such as soluble Ab, within the cerebrovascular system. In doing so, they eliminate critical elements involved in the etiology of Alzheimer's disease and new data suggest that novel TLR4 ligands can be used as therapeutic approaches to stimulate monocytes and other cells of the NVU (Michaud et al., 2013) . The NVU is also critically involved in the etiology of MS.
The inflammatory response taking place in the CNS has often been associated with progressive neuronal damage and chronic brain diseases. However, accumulating evidence now suggests that CNS-resident microglia and circulating monocytes may have more beneficial effects for neurons than previously thought. It appears likely that monocytic cells and the molecules they produce contribute to tissue repair and neuronal survival/regeneration in certain conditions but become detrimental in other situations. The apparent discrepancies between the harmful and beneficial effects of monocytic cells may be due, at least in part, to the differences in the manner and timing of their activation and in the way they interact with other cells of the NVU. Indeed, monocytic cells and other immune cells produce a different repertoire of cytokines, growth factors, proteases, free radicals, and other molecules depending on the cell subset involved and their state of activation that act not only on neurons but also in every cell of the NVU. As we begin to understand the molecular determinants that regulate the differentiation, polarization, and activation of these cells toward different phenotypes, and the molecular functions of these phenotypes, we will be able to make sense of the seemingly contradictory findings on the role of inflammation in AD and MS.
MS is traditionally considered to be the prototypical autoimmune inflammatory disease of the CNS, with a primary immune assault directed against central myelin antigens and oligodendrocytes. The activation of innate immune signaling pathways in CNS-resident microglia takes place early in the disease process, which is followed by a marked recruitment, proliferation, and activation of monocytes/macrophages in affected regions of the CNS; these monocytic cells show most of the characteristics of the M1 subset, characterized by a proinflammatory phenotype. Activated autoreactive T lymphocytes, including those of the Th1 and Th17 subsets, are also prominently represented in MS lesions and interact with monocytic cells to destroy the myelin. The cause of these abnormal interactions remains unknown.
AD, however, is not classically described as an inflammatory disease, but recent evidence suggests that circulating monocytes are key to the disease onset (Malm et al., 2010) . It is now well accepted that key receptors of the innate immune system are involved in the removal of Ab and may act as a natural defense mechanism to prevent Ab accumulation in the brain vascular system and the CNS. The critical question, then, is why do these receptors fail to remove Ab in the CNS of AD patients and in mouse models of AD? It is possible that the phagocytic properties of monocytes and microglia are decreased with aging and disease progression and/or that the balance between Ab production and clearance is disturbed in AD. It has been reported that macrophages of most AD patients do not transport Ab into endosomes and lysosomes and that monocyte-derived macrophages do not efficiently clear Ab (Fiala et al., 2005) . One possibility is that, in contrast to MS, monocytes may be polarized toward an anti-inflammatory phenotype (e.g., M2) rather than being proinflammatory in AD individuals. In support of the latter hypothesis is the observation that blocking signaling by the immunosuppressive cytokine TGFb1 in bone marrow-derived myeloid cells improved AD-like pathology in mice (Town et al., 2008) . We also found that the progressive cognitive decline and decrease in expression of numerous synaptic markers and neurotrophins in the brain of AD mice correlated with major changes in the proportions of peripheral blood monocyte subsets when compared with age-matched controls (Naert and Rivest, 2012) . Indeed, there is a defect in the production of circulating M1 monocytes in APP/PS1 mice, whereas the population of M2 monocytes remains normal in this mouse model of AD (Naert and Rivest, 2012) . Of great interest is that such a defect in monocyte frequency can be restored by systemic M-CSF treatments (Naert and Rivest, 2012) .
The AD/MS paradigm illustrates the complexity of innate immunity in the CNS, especially when using it as a therapeutic target for chronic diseases. It is now evident that simple repression of the whole system in a given disease will not yield enough results clinically. There is now a need to develop novel integrative approaches that take into account the role of microglial inflammation, astrocytic processes, the BBB sink, and the interaction between every cell of the CNS, in order to develop efficient ways to target such complex pathologies as AD and MS. MS is a complex chronic disease involving a host of cells with deregulated roles. The main culprits are autoreactive T cells specific for the myelin basic proteins (MBPs), which coat axons for optimal neuronal transmission. For yet unclear reasons, these T cells infiltrate massively into the CNS and induce demyelination leading to progressive physical and cognitive disabilities. Monocytic cells (monocytes, macrophages, microglia, etc.) are also very important in the development of the disease. Skewed toward a highly inflammatory activation state, these cells contribute to the disease by inefficient immunosuppression of autoreactive T cells but also by inducing, or at least not reducing, the infiltration of T cells into the CNS. Autologous hematopoietic stem cell transplantation has shown great promises in the clinic for the treatment of relapsing-remitting MS. Proposed curative mechanisms of this treatment include the depletion of autoreactive T cell lineage and the prolonged immunosuppression of T cells altogether by chemotherapeutic regimen. Under less stress by T cells, monocytic cells can now properly function as neuroprotective and immunosuppressive cells.
